NAD+ precursors are being studied for potential roles in cellular energy metabolism. Evidence in humans remains early-stage. NAD+ supplementation is not FDA-approved as a drug for energy or longevity indications.
Risks
- IV NAD+ may cause flushing, GI distress, chest tightness, or infusion-site reactions.
- Long-term safety profile in healthy adults is not fully established.
- Results are not guaranteed.